Introduction {#s1}
============

Leucopenia is defined by a lower-than-normal peripheral white blood cell (WBC) count. Leucopenia commonly arises from cancer chemotherapy or radiotherapy, viral infection, drug-induced reactions, and certain immune diseases \[[@B1]-[@B7]\]. Recent studies suggest that a single-nucleotide polymorphism may also cause leucopenia \[[@B8]\]. At present, leucogen, shark glycol, vitamin B4, and inosine have been used to treat leucopenia. However, these treatments fail in some cases, and novel approaches for treating leucopenia are needed. Recently, in China, Huangqi injection for the treatment of leucopenia has been reported in many clinical trials. These individual studies suggest that Huangqi injection may be useful for the treatment of leucopenia, but a systematic review has not been performed. Therefore, we conducted a meta-analysis of clinical controlled trials to assess the therapeutic value of Huangqi injection for the treatment of leucopenia.

Materials and Methods {#s2}
=====================

Inclusion criteria {#s2.1}
------------------

The clinical trials were clinically controlled studies and experimental groups were treated with Huangqi injection. Controls in the studies were treated with Western medicine as described in [Table 1](#pone-0083123-t001){ref-type="table"}. Outcome measures were effectiveness rates and WBC counts. WBC measurements were performed by an independent laboratory and measured in SI units (10^9^/L). When total WBCs were greater than 4.0×10^9^/L or elevated more than 1.0×10^9^/L in the peripheral blood arising from a drug intervention, treatments were considered to be effective. Before treatment, the baseline peripheral WBCs were comparable between the experimental group (Huangqi injection) and the control group (Western medicine) (*P*\>0.05). In this study, we restricted no clinical trials based on patient gender, race, or language of the publication.

10.1371/journal.pone.0083123.t001

###### Characteristics of the individual trials included in this study.

  **Author \[Reference\]**   **Published year**   **Cases E/C**   **Age (years) Range, mean**   **Sex Male/female**   **Etiopathogenesis**
  -------------------------- -------------------- --------------- ----------------------------- --------------------- ------------------------------------------------------------------
  Zhang MJ\[[@B15]\]         1999                 35/32           E: 18-50, 33 C: 20-56,37      E: 7/28 C: 19/23      Radiotherapy, chemotherapy, immunodiseases
  Dai Y\[[@B17]\]            1999                 68/27           25-76,55.6                    59/36                 Radiotherapy, chemotherapy
  Feng CL\[[@B10]\]          2000                 32/28           E: 40-79 C: 42-79             E: 14/18 C: 13/15     Infection
  Zhang YS\[[@B14]\]         2000                 58/54           E: 16-52,36 C: 15-56,34.6     E: 30/28 C: 32/22     Radiotherapy, chemotherapy, drug use, etc
  Gao P\[[@B16]\]            2000                 30/25           E: 15-56,32 C: 18-55,35       E: 10/20 C: 9/46      Radiotherapy, chemotherapy, viral infection, immunodiseases, etc
  Qu W\[[@B21]\]             2000                 32/28           E: 16-63,38.2 C: 15-56,34.6   E: 14/18 C: 12/16     Graves disease with tapazole
  Yang DS\[[@B11]\]          2001                 25/25           18-55,33.5                    21/29                 Radiotherapy, chemotherapy, drug use
  Mo WG\[[@B18]\]            2005                 30/30           E: 0-12,2.44 C: 0-11,2.99     E: 19/11 C: 17/13     Viral infection
  Tang JC\[[@B13]\]          2007                 23/22           13-64,50                      30/15                 Nasopharyngeal carcinoma patient with radiotherapy
  Wang HJ\[[@B20]\]          2007                 40/39           16-68,31.5                    6/73                  Systemic lupus erythematosus
  Xiao AQ\[[@B9]\]           2007                 26/25           33-73                         E: 14/12 C: 15/10     Ticlopidine use
  Mo WX\[[@B19]\]            2009                 20/20           E:16-54,28 C:18-52,26         E: 8/12 C: 9/11       Schizophrenia with clozapine
  Qin HZ\[[@B12]\]           2011                 35/32           E: 19-51,32 C: 22-55,36       E: 9/26 C: 10/22      Radiotherapy, chemotherapy, viral infection, immunodiseases, etc

E: experimental group, C: control group.

Exclusion criteria {#s2.2}
------------------

Duplicated literature, reviews, non-clinical studies, case observations, and non-injection formulae literature were excluded in this study.

Research strategy and data extraction {#s2.3}
-------------------------------------

"Huangqi" or "huang qi" or "astragalus" or "astragali" or "astragalus miltiorrhiza" or "Chinese traditional medicine herb" AND "leucopenia" or "leucocytopenia" or "leucopenia" or "aleucocytosis" or "hypolekocytosis" or "hypoleucocytosis" or "hypoleukemia" or "hypoleukia" or "hypoleukocytosis leucocytopenia" or "leucopenia" or "oligoleukocythemia" or "oligoleukocytosis" or "white blood count" were selected as the free-text terms or MeSH terms. The Chinese Biomedical Literature Database (CBM), Wanfang Database, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Full-text Database (VIP), PubMed, and EMBASE were searched. Data extraction and quality assessment were independently performed by two researchers \[CTZ and YL\] and any discrepancies were resolved by consensus or in consultation with a third reviewer \[CSZ\]. The lack of information in any study was supplemented by contact with the authors in charge of the clinical trials. The database retrieval process is shown in [Figure 1](#pone-0083123-g001){ref-type="fig"}.

![Flow diagram of literature retrieval.](pone.0083123.g001){#pone-0083123-g001}

Statistical analysis {#s2.4}
--------------------

Statistical analysis was performed using Cochrane RevMan 5.2 and STATA 11.0 software. Categorical variables were compared using odds ratios (OR), and continuous variables were compared using standard mean differences (SMD). A 95% confidence interval (CI) was calculated and the Chi-square test was used for heterogeneity of inclusion trials. Data of heterogeneity were studied using a random effects model; otherwise a fixed effects model was used. A funnel plot and Egger's test were employed to judge potential publication bias.

Results {#s3}
=======

Characteristics of included studies {#s3.1}
-----------------------------------

Thirteen articles \[[@B9]-[@B21]\] involving 841 subjects (experimental groups: 454 cases; the control groups: 387 cases) were included in this study. Causes of leucopenia were mainly viral infection, cancer chemotherapy, drug-induced reactions, and immune disorders. The general characteristics of the study are shown in [Table 1](#pone-0083123-t001){ref-type="table"}, and interventions, treatments, and outcomes are depicted in [Table 2](#pone-0083123-t002){ref-type="table"}.

10.1371/journal.pone.0083123.t002

###### The intervention measures of the individual studies included in this study.

  **Author**              **The regimens of intervention**                                                                               **Treatment**                                                     
  ----------------------- -------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- ----------
  Zhang MJ\[[@B15]\]      Huangqi injection (40 ml) were respectively added to a 5% glucose solution (250 ml), intravenously, qd         Oral leucogen, and batyl alcohol; energy mixture, intravenously   30 d
  Dai Y\[[@B17]\]         Huangqi injection (40 ml) were respectively added to a 5% glucose solution (250 ml), intravenously, qd         Oral batyl alcohol and leucogen                                   7-10 d
  Zhang YS\[[@B14]\]      Huangqi injection (40 ml) were respectively added to a 5% glucose solution (500 ml), intravenously, qd         Oral inosine, leucogen and batyl alcohol                          14 d
  Gao P\[[@B16]\]         Huangqi injection (40 ml) were respectively added to a 5% glucose solution (250 ml), intravenously, qd         Oral batyl alcohol, tid                                           30 d
  Tang JC\[[@B13]\]       Huangqi injection (40 ml) were respectively added to a 5% solution (250 ml), intravenously, qd                 Oral inosine                                                      49 d
  Mo WX\[[@B19]\]         Huangqi injection (20 ml) were respectively added to a 5% solution (250 ml), intravenously, qd                 Oral leucogen and vitamin B4                                      45 d
  Qin HZ\[[@B12]\]        Huangqi injection (40 ml) were respectively added to a 5% solution (250 ml), intravenously, qd                 Oral leucogen and batyl alcohol, energy mixture, intravenously    30 d
  Feng CL\[[@B10]\]^\#^   Huangqi injection (20-40 ml) were respectively added to a 5‑10% glucose solution (250 ml), intravenously, qd   Anti-infecion and symptomatic treatment                           15--21 d
  Qu W\[[@B21]\]^\#^      Huangqi injection (40 ml) were respectively added to a 5% solution (250 ml), intravenously, qd                 Oral tapazole                                                     28 d
  Yang DS\[[@B11]\]^\#^   Huangqi injection (40 ml) were respectively added to a 5% solution (250 ml), intravenously, qd                 Oral vitamin B4 and leucogen                                      30 d
  Mo WG\[[@B18]\]^\#^     Huangqi injection (5-10ml) were respectively added to a 5% solution (250 ml), intravenously, qd                Conventional antiviral and symptomatic treatment                  7 d
  Wang HJ\[[@B20]\]^\#^   Huangqi injection (40 ml) were respectively added to a 5% solution (250 ml), intravenously, qd                 Oral prednisone and leflunomide                                   2--4 w
  Xiao AQ\[[@B9]\]^\#^    Huangqi injection (40 ml) were respectively added to a 5% solution (250 ml), intravenously, qd                 Oral leucogen and batyl alcohol                                   30 d

^\#^: In the experimental group, interventional regimens included drugs of the control group other than Huangqi injection.

The quality assessment {#s3.2}
----------------------

The Jadad scale was scored by randomization, randomization methodology, double-blinding, withdrawals/dropouts, and allocation concealment \[[@B22]-[@B24]\]. The Jadad scores ranged from 0 to 2 ([Table 3](#pone-0083123-t003){ref-type="table"}), suggesting that the overall quality of the literature was lower.

10.1371/journal.pone.0083123.t003

###### Quality of clinical trial reports using the Jadad assessment scale.

  **Author\[reference\]**   **Randomization**   **Randomization methodology description**   **Double-blinding**   **Withdrawals/dropouts**   **Allocation concealment**   **Scores**
  ------------------------- ------------------- ------------------------------------------- --------------------- -------------------------- ---------------------------- ------------
  Zhang MJ\[[@B15]\]        No                  No                                          No                    No                         No                           0
  Dai Y\[[@B17]\]           Yes                 No                                          No                    No                         No                           1
  Feng CL\[[@B10]\]         No                  No                                          No                    No                         No                           0
  Zhang YS\[[@B14]\]        Yes                 No                                          No                    No                         No                           1
  Gao P\[[@B16]\]           Yes                 No                                          No                    No                         No                           1
  Qu W\[[@B21]\]            Yes                 No                                          No                    No                         No                           1
  Yang DS\[[@B11]\]         Yes                 Yes                                         No                    No                         No                           2
  Mo WG\[[@B18]\]           No                  No                                          No                    No                         No                           0
  Tang JC\[[@B13]\]         Yes                 No                                          No                    No                         No                           1
  Wang HJ\[[@B20]\]         Yes                 No                                          No                    No                         No                           1
  Xiao AQ\[[@B9]\]          Yes                 No                                          No                    No                         No                           1
  Mo WX\[[@B19]\]           Yes                 No                                          No                    No                         No                           1
  Qin HZ\[[@B12]\]          Yes                 No                                          No                    No                         No                           1

Meta-analyses of the effectiveness of Huangqi injection {#s3.3}
-------------------------------------------------------

Ten studies \[[@B9]-[@B18]\] described the effectiveness of Huangqi ([Figure 2](#pone-0083123-g002){ref-type="fig"}). Meta-analysis revealed an overall effectiveness rate in the experimental group that was higher than that in the control group \[OR = 6.69, 95% CI (4.14, 10.81), *P* \< 0.05; fixed effects model\] ([Figure 2](#pone-0083123-g002){ref-type="fig"}). The combined estimates of WBCs in the experimental group was also higher than that in the control group \[SMD=1.94, 95% CI (1.19-2.69), *P* \< 0.05; random effects model\] ([Figure 3](#pone-0083123-g003){ref-type="fig"}).

![Effectiveness of Huangqi injection for the treatment of leucopenia.\
Events: the numbers of the effective cases.](pone.0083123.g002){#pone-0083123-g002}

![Effect of Huangqi injection on white blood cell.](pone.0083123.g003){#pone-0083123-g003}

Subgroup analyses of Huangqi injection versus Western medicine {#s3.4}
--------------------------------------------------------------

The pool effectiveness rate in Huangqi injection treatment group was higher than that in the Western medicine treatment group \[OR = 7.06, 95% CI (4.11, 12.15), *P* \< 0.05; fixed effects model\] ([Figure 2](#pone-0083123-g002){ref-type="fig"}). WBC counts in the Huangqi injection treatment group were higher than those in the control group \[SMD=0.82, 95% CI (0.38, 1.25), *P* \< 0.05; random effects model\] ([Figure 3](#pone-0083123-g003){ref-type="fig"}).

Subgroup analyses of Huangqi injection combined with Western medicine versus Western medicine {#s3.5}
---------------------------------------------------------------------------------------------

There was significant difference in the pool effectiveness rate between the experimental group with Huangqi injection combined with Western medicine and the control group with Western medicine \[OR = 5.64, 95% CI (2.04, 15.58), *P* \< 0.05; fixed effects model\] ([Figure 2](#pone-0083123-g002){ref-type="fig"}). WBCs in the experimental group were significantly higher than those in the control group \[SMD=1.88, 95% CI (1.06, 2.71), *P*\<0.05; random effects model\] ([Figure 3](#pone-0083123-g003){ref-type="fig"}).

Side effects {#s3.6}
------------

In this study, five reports \[[@B9],[@B12],[@B13],[@B16],[@B19]\] confirmed that no side effects in clinical trials were observed. The remaining reports did not mention adverse effects. Thus, we could not evaluate adverse effects due to this deficit.

Publication bias {#s3.7}
----------------

There was no publication bias according to the results of Egger's test performed by STATA 11.0 (*P* = 0.264). The funnel plot drawn by Cochrane Revman 5.2 was basically symmetric ([Figure 4](#pone-0083123-g004){ref-type="fig"}).

![Funnel plots based on data of overall effectiveness.](pone.0083123.g004){#pone-0083123-g004}

Discussion {#s4}
==========

Recently, in China, apart from treating leucopenia, Huangqi injection has been widely used to treat chronic hepatitis \[[@B25]-[@B27]\], cirrhosis \[[@B28]\], chronic heart failure \[[@B29],[@B30]\], chronic nephritis \[[@B31]-[@B33]\], and diabetic nephropathy \[[@B34],[@B35]\].

Huangqi injection is derived from the *Radix Astragali Mongolici* root using ethanol. Modern pharmacological studies demonstrated that astragalus flavonoids, an effective component of Huangqi, can eliminate radiation toxicity and increase granulocyte colony-stimulating factor to promote stem cell proliferation \[[@B36]\]. In addition, Huangqi can regulate humoral immunity, inhibit proliferation of tumor cells and reduce chemotherapeutic toxicity \[[@B37]-[@B41]\].

According to this meta-analysis, Huangqi injection was more efficacious than the Western medicine control group. Subgroup analyses revealed that the overall effectiveness rates in the experimental group receiving Huangqi injection alone or combined with Western medicine was higher compared with Western medicine alone.

We noted that five studies suggested that clinical trial side effects were not observed. Whereas, according to a review of 83 studies \[[@B42]\] regarding adverse reactions in response to Huangqi injection (1995--2008) by the Evidence Based Medicine Centre, Tianjin University of Traditional Chinese Medicine, China, data suggest that only moderate reactions were observed. Most of these were dermal allergenic reactions; no deaths were reported. These findings suggest that Huangqi may be safe and may have a potential clinical value in the treatment and prevention of leucopenia. Considering reports that Huangqi injection could enhance immunity and inhibit tumors, use of Huangqi to treat cancer patients during radiotherapy and chemotherapy may be possible. Interestingly, the previous Cochrane systematic review \[[@B43]\] reported that the proportion of patients with leucopenia was significantly lower in the groups treated with Huangqi injection in addition to chemotherapy and the pooled estimate of absolute rate reduction was 36% (95% CI: 21% to 51%), suggesting that Huangqi injection may be used as a preventative treatment for leucopenia during chemotherapy. However, in this present study, we didn't conduct a meta-analysis on the preventative treatment.

Although no publication bias was confirmed according to the results of Egger's test, the meta-analysis did have some limitations. These may decrease the validity of evidence-based medicine within this meta-analysis. The main limitations were poor quality of included studies and in our meta-analysis, no study accounted for withdrawals/dropouts and only one provided a description of randomization methodology. Neither double-blind nor concealed allocation studies were mentioned in the included literature. Moreover, available data about follow-up regarding long-term efficacy and safety were insufficient. Based on these disadvantages, a treatment effect of this size seems quite unlikely. It must be emphasized that such trials should be randomized and ideally placebo controlled.

Fortunately, in the included studies, WBC counts were performed by independent laboratory personnel and the staff was blinded to the treatment drug group/patient group. These data suggest that the outcome evaluation was reliable.

Presently, most clinical trials published in Chinese medical journals were of poor quality with respect to methodological design according to the Jadad scale \[[@B41],[@B44]\]. Future trials to evaluate Huangqi should incorporate clinical trial registration and adoption of the international reporting criteria such as CONSORT, STROBE and PRISMA. These procedures would drastically elevate the validity of the clinical trials.

Conclusions {#s5}
===========

The validity of this meta-analysis was limited by the overall poor quality of the included studies. Huangqi injection may have potential clinical value in the treatment of leucopenia, but further studies are warranted, especially rigorous and well-designed multi-center trials.
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